公开(公告)号：US20190062276A1

公开(公告)日：2019-02-28

申请号：US15927426

申请日：2018-03-21

Applicant: Amgen Inc.

Inventor： Michael D. Bartberger ,  Ana Gonzalez Buenrostro ,  Hilary Plake Beck ,  Xiaoqi Chen ,  Richard Victor Connors ,  Jeffrey Deignan ,  Jason A. Duquette ,  John Eksterowicz ,  Benjamin Fisher ,  Brian M. Fox ,  Jiasheng Fu ,  Zice Fu ,  Felix Gonzalez Lopez De Turiso ,  Michael W. Gribble, JR. ,  Darin J. Gustin ,  Julie A. Heath ,  Xin Huang ,  XianYun Jiao ,  Michael G. Johnson ,  Frank Kayser ,  David John Kopecky ,  SuJen Lai ,  Yihong Li ,  Zhihong Li ,  Jiwen Liu ,  Jonathan D. Low ,  Brian S. Lucas ,  Zhihua Ma ,  Lawrence R. McGee ,  Joel McIntosh ,  Dustin L. McMinn ,  Julio C. Medina ,  Jeffrey Thomas Mihalic ,  Steven H. Olson ,  Yosup Rew ,  Philip M. Roveto ,  Daqing Sun ,  Xiaodong Wang ,  Yingcai Wang ,  Xuelei Yan ,  Ming Yu ,  Jiang Zhu

IPC: C07D211/76 ,  C07D279/02 ,  C07D405/12 ,  C07D405/04 ,  C07D491/153 ,  C07D407/04 ,  C07D401/12 ,  C07D401/06 ,  C07D417/06 ,  C07D413/06 ,  C07D491/08 ,  C07D401/04 ,  C07D471/10 ,  C07D221/20 ,  C07D417/14 ,  C07D498/08 ,  C07D409/04 ,  C07D407/06 ,  C07D417/12 ,  C07D498/14 ,  C07D409/12 ,  C07D498/20

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

公开(公告)号：US20140011796A1

公开(公告)日：2014-01-09

申请号：US14025688

申请日：2013-09-12

Applicant: AMGEN INC.

Inventor： Michael David BARTBERGER ,  Ana Gonzalez Buenrostro ,  Hilary Plake Beck ,  Xiaoqi Chen ,  Richard Victor Connors ,  Jeffrey Deignan ,  Jason Duquette ,  John Eksterwicz ,  Benjamin Fisher ,  Brian Matthew Fox ,  Jiasheng Fu ,  Zice Fu ,  Felix Gonzalez Lopez De Turiso ,  Michael William Gribble ,  Dann James Gustin ,  Julie Anne Heath ,  Xin Huang ,  Xianyun Jiao ,  Michael Johnson ,  Frank Kayser ,  David John Kopecky ,  Sujen Lai ,  Yihong Li ,  Zhihong Li ,  Jiwen Liu ,  Jonathan Dante Low ,  Brian Stuart Lucas ,  Zhihua Ma ,  Lawrence R. McGee ,  Joel McIntosh ,  Dustin McMinn ,  Julio Cesar Medina ,  Jeffrey Thomas Mihalic ,  Steven Howard Olson ,  Yosup Rew ,  Philip Marley Roveto ,  Daqing Sun ,  Xiaodong Wang ,  Yingcai Wang ,  Xuelei Yan ,  Ming Yu ,  Jiang Zhu

IPC: C07D211/76 ,  C07D417/12 ,  C07D413/06 ,  C07D471/10 ,  C07D409/04 ,  C07D401/04 ,  C07D279/02 ,  C07D491/08 ,  C07D498/08 ,  C07D417/14 ,  C07D491/153 ,  C07D417/06 ,  C07D401/06 ,  C07D405/04

CPC classification number: C07D211/76 ,  C07D221/20 ,  C07D279/02 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D407/04 ,  C07D407/06 ,  C07D409/04 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/10 ,  C07D491/08 ,  C07D491/153 ,  C07D498/08 ,  C07D498/14 ,  C07D498/20

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.